New and emerging technologies for genetic toxicity testing
| Autor: | Jan van Benthem, David Jacobson-Kram, Véronique Thybaud, Masamitsu Honma, Rosalie K. Elespuru, Richard M. Walmsley, Jiri Aubrecht, Russell T. Naven, Stephen D. Dertinger, Paul D. White, George R. Douglas, Jennifer C. Sasaki, Marilyn J. Aardema, R. Daniel Benz, Albert J. Fornace, Marlies De Boeck, Patricia A. Escobar, Anthony M. Lynch, Eiji Yamamura, Robert H. Schiestl, James H. Kim, James F. Rusling |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Technology
Weight of evidence Mutagenicity Tests Epidemiology business.industry Emerging technologies Consensus Development Conferences as Topic International Cooperation Health Toxicology and Mutagenesis Risk Assessment Hazard Chromosome aberration Biotechnology Genotoxicity testing Engineering management Animals Humans Workgroup business Risk assessment Genetics (clinical) Mutagens Genetic Toxicology |
| Zdroj: | Environmental and Molecular Mutagenesis. 52:205-223 |
| ISSN: | 0893-6692 |
| DOI: | 10.1002/em.20614 |
| Popis: | The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing established an Emerging Technologies and New Strategies Workgroup to review the current State of the Art in genetic toxicology testing. The aim of the workgroup was to identify promising technologies that will improve genotoxicity testing and assessment of in vivo hazard and risk, and that have the potential to help meet the objectives of the IVGT. As part of this initiative, HESI convened a workshop in Washington, DC in May 2008 to discuss mature, maturing, and emerging technologies in genetic toxicology. This article collates the abstracts of the New and Emerging Technologies Workshop together with some additional technologies subsequently considered by the workgroup. Each abstract (available in the online version of the article) includes a section addressed specifically to the strengths, weaknesses, opportunities, and threats associated with the respective technology. Importantly, an overview of the technologies and an indication of how their use might be aligned with the objectives of IVGT are presented. In particular, consideration was given with regard to follow-up testing of positive results in the standard IVGT tests (i.e., Salmonella Ames test, chromosome aberration assay, and mouse lymphoma assay) to add weight of evidence and/or provide mechanism of action for improved genetic toxicity risk assessments in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text